GS-9721

**GS-9721** is an investigational HIV broadly neutralizing antibody derived from **PGT121** and engineered to enhance Fc-mediated effector function and extend half-life. It binds the HIV-1 envelope, with activity directed against envelope components including **gp120** and functionally the **gp41-associated Env trimer complex**, and was developed by **Gilead** as part of HIV remission or cure-oriented combination strategies rather than as a marketed antiretroviral. Preclinical studies in SHIV-infected rhesus macaques evaluated GS-9721 together with the TLR7 agonist vesatolimod, where the Fc-enhanced antibody format was intended to improve antiviral immune clearance through stronger antibody-dependent cellular cytotoxicity and phagocytosis. Publicly available information indicates the program remained in early development and no approved commercial product or established clinical indication has been identified.

Other names

PGT121 analogPGT-121 analogPGT 121 analog